entertainment -WSS

entertainment

author：leisure time 2025-09-05 09:10:56 - browse：5

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Readers discuss the intersection of pregnancy and addiction

focus

WSS

Adam's Take: Intra

Pfizer, Moderna say biotech, pharma drug development is a sprint

5 takeaways from STAT's examination of Zynex Medical

STAT Virtual Event: ASCO Recap, Live!

Pfizer, Moderna say biotech, pharma drug development is a sprint

Stephen Quake on the Chan Zuckerberg quest to conquer disease

entertainment

entertainment

entertainment

How one medical school became remarkably diverse

Steward Health Care expansion into Malta flopped

Medicare details structure of new drug price negotiation program

Surgeons perform first xenotransplant using CRISPR'd pig kidney

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

U.K. officials, researchers try to ease path for bespoke genetic treatments

Drug repurposing or repositioning? The language matters

Chinese researcher claims birth of first gene

Wildfire smoke exposes gaps in outdoor worker protections

How faith leaders like me can help address America's obesity epidemic

leisure time

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Stephen Quake on the Chan Zuckerberg quest to conquer disease

With Wegovy coverage, Medicare patients may face high costs

Pregnancy ages women, but effects reverse after delivery

What Kate Middleton's cancer revelation might teach the world

hotspot

focus

focus

focus